Relugolix + Strong Cyp3a4 And P Glycoprotein Inducers Interaction
Majorinteraction on record
Description
Co-administration decreases relugolix exposure, which may reduce therapeutic effects. If unavoidable, increase ORGOVYX dose to 240 mg once daily.
Mechanism
Relugolix is a P-gp and CYP3A substrate; combined induction decreases relugolix exposure
Source: NLP:relugolix